Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;8(1):e000984.
doi: 10.1136/jitc-2020-000984.

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management

Affiliations

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management

Jarushka Naidoo et al. J Immunother Cancer. 2020 Jun.

Abstract

Immune-related (IR)-pneumonitis is a rare and potentially fatal toxicity of anti-PD(L)1 immunotherapy. Expert guidelines for the diagnosis and management of IR-pneumonitis include multidisciplinary input from medical oncology, pulmonary medicine, infectious disease, and radiology specialists. Severe acute respiratory syndrome coronavirus 2 is a recently recognized respiratory virus that is responsible for causing the COVID-19 global pandemic. Symptoms and imaging findings from IR-pneumonitis and COVID-19 pneumonia can be similar, and early COVID-19 viral testing may yield false negative results, complicating the diagnosis and management of both entities. Herein, we present a set of multidisciplinary consensus recommendations for the diagnosis and management of IR-pneumonitis in the setting of COVID-19 including: (1) isolation procedures, (2) recommended imaging and interpretation, (3) adaptations to invasive testing, (4) adaptations to the management of IR-pneumonitis, (5) immunosuppression for steroid-refractory IR-pneumonitis, and (6) management of suspected concurrent IR-pneumonitis and COVID-19 infection. There is an emerging need for the adaptation of expert guidelines for IR-pneumonitis in the setting of the global COVID-19 pandemic. We propose a multidisciplinary consensus on this topic, in this position paper.

Keywords: autoimmunity; guidelines as topic; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JN: research funding: Merck, AstraZeneca; consulting/advisory board: Bristol-Myers Squibb, AstraZeneca, Roche/Genentech; honoraria: Bristol-Myers Squibb, Merck, AstraZeneca. DBJ: advisory boards/consulting: Array Biopharma, BMS, Jansen, Merck, Novartis; research funding: BMS, Incyte. JRB: advisory boards/consulting: Amgen, BMS, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Sanofi; research funding: AstraZeneca, BMS, Genentech/Roche, Merck, RAPT Therapeutics Inc., Revolution Medicines; data and safety monitoring board/committees: GlaxoSmithKline, Sanofi. MN: advisory boards/consulting: Daiichi Sankyo, AstraZeneca; research funding: Merck, Canon Medical Systems, AstraZeneca, Daiichi Sankyo; honorarium: Roche. PMF: advisory boards/consulting: Abbvie, AstraZeneca, BMS; research funding: AstraZeneca, BMS, Kyowa, Novartis, Corvus.

Figures

Figure 1
Figure 1
Representative images for COVID-19 (A–D) and immune-related (IR) pneumonitis (E–H). (A) Radiograph with opacities in bilateral upper and mid-lung fields. (B) Axial chest CT with diffuse bilateral ground-glass opacities (GGOs) with areas of consolidative opacities. (C) Axial chest CT with predominantly peripheral GGOs associated with interlobular septal thickening. (D) Axial chest CT with bilateral peripheral interstitial opacities with GGOs, reticular opacities, consolidation and interlobular septal thickening. (E) Radiograph of patient with immune-related pneumonitis, demonstrating left upper lobe predominant airspace opacities. (F) Axial chest CT of same patient demonstrates bilateral GGOs with interlobular septal thickening. (G) Axial chest CT demonstrating cryptogenic organizing pneumonia pattern of IR-pneumonitis with multifocal discrete areas of consolidation and bilateral GGOs. (H) Axial chest CT demonstrating a non-specific interstitial pneumonia pattern of IR-pneumonitis with increased interstitial markings, interlobular septal thickening, subpleural GGOs and reticular opacities. (A–D) images abstracted from Zu et al, Shi et al (E–F) images abstracted fromNaidoo et al, Al-Shamsi et al, Licenses to reproduce images obtained for and, licenses for and in process.

Similar articles

Cited by

References

    1. Naidoo J, Wang X, Woo KM, et al. . Pneumonitis in patients treated with Anti-Programmed Death-1/Programmed death ligand 1 therapy. J Clin Oncol 2017;35:709–17. 10.1200/JCO.2016.68.2005 - DOI - PMC - PubMed
    1. Suresh K, Voong KR, Shankar B, et al. . Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 2018;13:1930–9. 10.1016/j.jtho.2018.08.2035 - DOI - PubMed
    1. Brahmer JR, Lacchetti C, Schneider BJ, et al. . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714–68. 10.1200/JCO.2017.77.6385 - DOI - PMC - PubMed
    1. Puzanov I, Diab A, Abdallah K, et al. . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group. J Immunother Cancer 2017;5:95. 10.1186/s40425-017-0300-z - DOI - PMC - PubMed
    1. Thompson JA. New NCCN guidelines: recognition and management of Immunotherapy-Related toxicity. J Natl Compr Canc Netw 2018;16:594–6. 10.6004/jnccn.2018.0047 - DOI - PubMed

MeSH terms

Substances